NCT05022342 2026-02-23
SPEAR
Novartis
Completed
Clinical Trials
4 trialsNCT04967248 2025-12-04
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Novartis
Terminated
NCT05293470 2025-07-09
A Post Marketing Surveillance on Piqray in Korea
Novartis
Recruiting
NCT04285723 2023-02-09
EPIK-P1
Novartis
Completed